A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes

Trial Profile

A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2015

At a glance

  • Drugs Bempedoic acid (Primary)
  • Indications Hyperlipidaemia
  • Focus Therapeutic Use
  • Sponsors Esperion Therapeutics
  • Most Recent Events

    • 02 May 2013 Primary endpoint 'Reduction in LDL-cholesterol-level' has been met.
    • 02 May 2013 Results presented at the Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB) 2013 Scientific Sessions and reported in a Esperion Therapeutics media release.
    • 07 Jan 2013 The full data from this trial will be presented at a future scientific meeting, according to an Esperion Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top